Bank of New York Mellon Corp purchased a new position in Certara, Inc. (NASDAQ:CERT – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 731,012 shares of the company’s stock, valued at approximately $4,788,000. Bank of New York Mellon Corp owned approximately 0.47% of Certara at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. Northwestern Mutual Wealth Management Co. boosted its position in shares of Certara by 2,733.3% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after buying an additional 2,870 shares during the period. Osaic Holdings Inc. increased its holdings in Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after buying an additional 1,175 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in Certara by 499.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after buying an additional 4,930 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in Certara during the second quarter worth approximately $83,000. Finally, Gamco Investors INC. ET AL purchased a new position in Certara in the fourth quarter valued at approximately $90,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets A number of research analysts have recently commented on CERT shares. Robert W. Baird dropped their price objective on shares of Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday, May 12th. Barclays lifted their target price on Certara from $6.50 to $7.50 and gave the stock an “equal weight” rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded Certara from a “sell (e+)” rating to a “sell (d)” rating in a report on Wednesday, August 5th. BMO Capital Markets cut their price target on shares of Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Tuesday, May 12th. Finally, Morgan Stanley dropped their target price on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Certara currently has a consensus rating of “Hold” and an average target price of $8.28.
Get Our Latest Report on CERT Certara Stock Performance NASDAQ:CERT opened at $7.94 on Friday. The firm’s 50-day moving average is $7.63 and its 200-day moving average is $6.52. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -17.64 and a beta of 1.40. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.55 and a current ratio of 2.55. Certara, Inc. has a 52-week low of $4.45 and a 52-week high of $13.88.
Certara (NASDAQ:CERT – Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). The business had revenue of $93.27 million for the quarter, compared to the consensus estimate of $98.09 million. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.Certara’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.07 EPS. Equities research analysts anticipate that Certara, Inc. will post 0.22 earnings per share for the current year.
Certara Profile (Free Report)
Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.
The company’s offerings are divided into software tools and consulting services.
Featured Articles Five stocks we like better than Certara Revolution Medicines Got Its Breakthrough—What Moves It Next? Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.
AUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Market Updates News Commentary - Earnings season in life sciences technology has just delivered an unusually clean verdict. The company that owns the industry’s data and systems of record beat and jumped. The company selling model-informed software into the same customers missed and fell by roughly the same amount on the day. The AI-native discovery company reported a fraction of the revenue analysts expected. Read together, those three results say something specific about where value is accruing in AI-enabled drug discovery, and it is not where most of the narrative has been pointed.
Companies mentioned in today’s commentary include: MindWalk Holdings Corp. (Nasdaq: HYFT), Veeva Systems Inc. (NYSE: VEEV), Illumina, Inc. (Nasdaq: ILMN), Certara, Inc. (Nasdaq: CERT), and Recursion Pharmaceuticals, Inc. (Nasdaq: RXRX).
Key Takeaways
The durable asset sits below the model. Foundation models are licensed, fine-tuned and replaced on a cycle now measured in months. The connected representation of biology those models run on is built once and curated for decades. MindWalk Holdings Corp. is selling the second thing.
Twenty years of curation, quantified. HYFT® Technology powers a function-aware representation of biology spanning sequence and structural biology, described by the Company as a continuously evolving biological representation of 660 million patterns and 25 billion relationships.
Three layers that stack rather than compete. HYFT® Technology powers the representation, ReefIQ™ is the biological context layer launched June 10, 2026, and LensAI™ is the reasoning layer. LensAI is already in contracted, recurring arrangements with life-sciences customers today.
Fiscal 2026 was the first year it showed in the numbers. Revenue rose 46% to C$15.6 million from C$10.6 million, gross margin expanded to 58.8% from 53.9%, and the net loss from continuing operations narrowed by more than half.
Still a micro-cap with a fee-for-service base. Management has described recurring platform revenue as modest and not yet significant to the fiscal 2026 total, and the Company remains unprofitable. The contracted arrangements referenced above are not quantified.
Three Results, One Message
Start with the incumbent. Veeva Systems Inc. (NYSE: VEEV) reported quarterly revenue of $928 million, up 17.6% year over year, with adjusted earnings of $2.35 per share and full-year guidance lifted to roughly $3.68 billion. The shares rose sharply on the print. Chief Executive Officer Peter Gassner has framed the company’s AI opportunity in terms that are worth reading carefully: with core systems of record spanning the industry’s most critical functions and unique datasets, the company can deliver industry-specific AI deeply integrated into its applications.
Now the contrast. Certara, Inc. (Nasdaq: CERT) reported revenue of $93.3 million, up 1%, with adjusted earnings of $0.08 per share against a $0.10 consensus, and the shares fell around 16%. Software revenue grew 4% while services fell 3%. The company reaffirmed full-year guidance and pointed to AI-driven product development, but the market was unmoved.
And the AI-native end of the spectrum. Recursion Pharmaceuticals, Inc. (Nasdaq: RXRX) reported second quarter revenue of roughly $7.7 million against analyst expectations closer to $12 million. The company carries a substantial cash position and a slate of clinical readouts ahead, but the quarter did not demonstrate a business converting AI capability into revenue at pace.
The pattern is not subtle. What got paid for was proprietary data and systems of record. What did not was software sold into the same customers without that underlying data position, and AI capability without a commercial engine attached. That is the distinction MindWalk has organized its entire business around, and it is the reason the company argues the layer beneath the model is where the value settles.
What MindWalk Actually Sells
MindWalk Holdings Corp. (Nasdaq: HYFT), founded in 1983 and built on more than 40 years of biology heritage, is a Bio-Native AI company building the BioIntelligence infrastructure that life sciences AI and agentic AI require. Its proprietary HYFT® Technology powers a function-aware representation of biology organized around HYFT pattern-objects spanning sequence and structural biology, refined over twenty years of curation into a continuously evolving biological representation of 660 million biological patterns and 25 billion relationships that enriches data at ingestion and compounds in analytical value with every program run on the platform.
The product architecture resolves into three layers. HYFT® Technology powers the biological representation. ReefIQ™, launched June 10, 2026, is the biological context layer: it harmonizes a client’s discovery data, links it to MindWalk’s biological representation foundation, preserves provenance and program history, and exposes governed, queryable context. LensAI™ is the reasoning and application layer, operating on that context to support retrieval, analysis, target discovery, candidate diligence, hypothesis generation and portfolio decision support, and to host agentic AI workflows. LensAI is already in contracted, recurring arrangements with life-sciences customers today.
"In life-sciences AI, the durable advantage is not the model a team licenses but the biological context it can reason over. Biology is connected by evolutionary constraint; discovery data arrives fragmented across files and systems, and that gap is where insight is lost. ReefIQ is designed to close it, preserving what every program learns, including the programs that fail, as governed context rather than isolated files. In a regulated setting, that is what makes reasoning trustworthy, and trustworthy is what compounds into the clinic," said Dr. Jennifer Bath, PhD, CEO and President of MindWalk Holdings Corp.
The observation about failed programs deserves more attention than it usually gets. The most expensive information a pharmaceutical company owns is the record of what did not work and why, and it is routinely the least well preserved, scattered across departed teams, retired systems and file formats chosen by whoever ran the experiment. A context layer that retains it is not a convenience feature. It is the difference between an organization that learns and one that repeats itself.
Follow the complete story on Market Updates
The Fiscal 2026 Numbers
For the year ended April 30, 2026, revenue grew 46% to C$15.6 million from C$10.6 million, gross margin expanded to 58.8% from 53.9%, and the net loss from continuing operations narrowed by more than half. The Company divested its Netherlands subsidiary, completed its rebranding from ImmunoPrecise Antibodies Ltd., regained Nasdaq listing compliance organically without a reverse split or dilution, and was subsequently added to the Russell 3000E and Russell Microcap Indexes. Results and filings are available through the Company’s investor relations newsroom and on EDGAR.
Two developments since year end frame the direction. The Company filed a European patent application building on its foundational HYFT patent estate. And on July 23, 2026, at AMD’s Advancing AI 2026 event in San Francisco, MindWalk presented the first public demonstration of ReefIQ™ running on AMD Instinct™ accelerators. MindWalk participated as a selected featured exhibitor; that selection does not imply endorsement, sponsorship, partnership or any commercial relationship with AMD beyond the showcase itself.
The scale gap between the Company and the names above should be stated rather than implied. Veeva reported more revenue in a single quarter than MindWalk’s total revenue for all of fiscal 2026, by orders of magnitude. Illumina raised full-year guidance to a range above US$4.6 billion. MindWalk is a micro-cap reporting in Canadian dollars, filing as a foreign private issuer on Form 20-F, with fiscal 2026 revenue of C$15.6 million. Nothing about the argument that context is the durable layer makes a small company a large one.
What Could Go Against It
MindWalk remains unprofitable, and revenue is still primarily fee-for-service discovery work rather than recurring platform revenue. Management has described the recurring platform component as modest and not yet significant to the fiscal 2026 total. The contracted, recurring arrangements referenced in this article are not quantified, and specific customers, deployment counts and contract values have not been disclosed.
Operating expenses in the commercial organization rose during the year with no guidance provided on where they go next, fourth quarter revenue came in below analyst estimates, and the shares traded lower after the print. The Company competes against far larger and better capitalized businesses, several of which are named above, and a patent application is an application rather than a grant. Readers should review the Company’s filings with the U.S. Securities and Exchange Commission and on SEDAR+ in full.
The Rest Of The Field
The four companies below are referenced solely as market and sector context. Each is a larger, established, revenue-generating business, and none of them is a peer, competitor or financial comparable of the profiled company. They are named because their most recent results, taken together, illustrate which layer of the AI-in-biology stack the market is currently rewarding.
Veeva Systems Inc. (NYSE: VEEV) provides cloud software, data and consulting to the global life sciences industry, and is the closest thing the sector has to an incumbent data layer. In its most recently reported quarter, revenue rose 17.6% year over year to $928 million with adjusted earnings of $2.35 per share, both ahead of consensus, and full-year revenue guidance was lifted to approximately $3.68 billion. The shares rose sharply on the release.
Management attributed the quarter to accelerating adoption of its AI products alongside strong core execution, describing it as the company’s best CRM quarter ever. Veeva operates at a scale entirely different from the profiled company and is included to show what the market pays for when proprietary industry data sits underneath an AI product rather than beside it.
Illumina, Inc. (Nasdaq: ILMN) sits at the instrument layer, generating much of the sequence data the rest of the field reasons over. In results announced July 30, 2026, second quarter revenue was $1.16 billion, up 9.5% year over year, with GAAP diluted earnings per share of $1.35 and non-GAAP diluted earnings per share of $1.31, and non-GAAP operating margin of 22.5%.
The company raised full-year 2026 revenue guidance to a range of $4.60 billion to $4.64 billion and non-GAAP diluted earnings per share guidance to $5.30 to $5.40. Chief Executive Officer Jacob Thaysen pointed to clinical customers expanding sequencing-intensive applications and continued demand for the NovaSeq X platform. Notably, the shares traded lower the following morning despite the raise, which is a reasonable reminder that beating and guiding higher does not guarantee a positive reaction in this sector.
Certara, Inc. (Nasdaq: CERT) is a global leader in model-informed drug development, selling biosimulation software and services into the same pharmaceutical customers. In results reported August 4, 2026, second quarter revenue from continuing operations was $93.3 million, up 1% year over year, with software revenue of $48.8 million up 4% and services revenue of $44.5 million down 3%. Adjusted EBITDA was $26.2 million, down 3%.
Adjusted earnings of $0.08 per share came in below the $0.10 consensus and revenue fell short of expectations, and the shares dropped around 16%. The company reaffirmed full-year revenue guidance of $367 million to $382 million, completed a $100 million share repurchase program and authorized an additional $50 million, and continues a reorganisation following the divestiture of its Regulatory and Medical Writing business. Certara is the clearest illustration in this group that selling software into pharma is not by itself the same trade as owning the data underneath it.
Recursion Pharmaceuticals, Inc. (Nasdaq: RXRX) represents the AI-native discovery end of the field, building its own pipeline on a proprietary platform rather than selling infrastructure to others. Second quarter revenue was reported at roughly $7.7 million, below analyst expectations closer to $12 million, with a loss per share modestly wider than consensus.
The company has narrowed its net loss year over year, lowered its cash operating expense guidance, and holds a cash position it has indicated funds operations into early 2028, with multiple clinical readouts expected. It is included here because it is the purest public expression of the thesis that AI capability alone creates value, and because its results to date show how long the distance between capability and revenue can be.
What To Watch
The markers for MindWalk are commercial rather than scientific from here. Whether recurring platform revenue moves from modest to material is the single number that matters, and it is the one the Company has not yet quantified. Alongside it: whether ReefIQ™ deployments convert into named, disclosed customers, whether the European patent application is granted, and whether operating expenses in the commercial organization stabilize now that the go-to-market build is underway.
The wider question is whether the pattern in this earnings season holds. If the market continues to pay for proprietary data positions and discount software and models sold without them, then a company whose entire asset is a curated biological representation is positioned in the right part of the stack. That is an argument about position, not about execution, and it does not make a micro-cap with C$15.6 million of revenue and no profitability a safe holding. It makes it a company worth understanding before deciding.
Track the Signals Before the Crowd
The best positioning happens before the crowd catches on. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow, and trending tickers as they form, so you see attention building instead of chasing it. Watch it live at eagle-eye.dev.
[1] MindWalk Holdings Corp. corporate disclosures, news releases and filings (fiscal 2026 results for the year ended April 30, 2026, the ReefIQ launch, HYFT Technology and LensAI descriptions, the European patent application, the AMD Advancing AI 2026 showcase, Nasdaq compliance and index inclusion). Filings are available on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca.
[2] Public disclosures, filings and earnings releases of the referenced companies (Veeva Systems Inc., Illumina, Inc., Certara, Inc. and Recursion Pharmaceuticals, Inc.)
DISCLAIMER:
Nothing in this publication should be considered personalized financial advice. We are not licensed under securities laws to address your particular financial situation, and no communication from us should be deemed personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor a recommendation to buy or sell any security. We hold no investment licenses and are neither licensed nor qualified to provide investment advice. The material in this article is intended to be strictly informational and is never to be construed or interpreted as research material. All readers are strongly urged to perform their own research and due diligence and to consult a licensed financial professional before considering any level of investing in stocks.
This article is being distributed for Market Equities Limited, a company incorporated under the laws of Ireland ("MEL"), which wholly owns and operates Market Updates. MEL has been paid a fee for MindWalk Holdings Corp. advertising and digital media from Creative Direct Marketing Group ("CDMG"). MEL has not been paid a fee directly by MindWalk Holdings Corp., and MEL is not affiliated with, and is a separate and independent entity from, CDMG and MindWalk Holdings Corp. MEL also expects to receive further compensation as part of an ongoing digital media effort to increase visibility for the company. No further notice will be given, but let this disclaimer serve as notice that all material, including this article, has been reviewed and approved by MindWalk Holdings Corp. and CDMG.
This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged not to use this publication as the basis for any investment decision.
MEL and its owner/operators do not own any shares of MindWalk Holdings Corp., but reserve the right to buy and sell shares of MindWalk Holdings Corp. at any time without any further notice commencing immediately and ongoing, in the open market, through private placements, and/or through other investment vehicles. There may also be third parties who hold shares of MindWalk Holdings Corp. and may liquidate their shares, which could have a negative effect on the price of the stock.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this publication is not trustworthy unless verified by their own independent research. Because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. Be extremely careful, investing in securities carries a high degree of risk; you may lose some or all of your investment.
Cautionary Note Regarding Financial Information and Corporate History: MindWalk Holdings Corp. was formerly ImmunoPrecise Antibodies Ltd. and was renamed in September 2025. Financial figures presented for the profiled company are as reported by the Company for the fiscal year ended April 30, 2026 and are stated in Canadian dollars unless otherwise noted. They are presented as reported by the Company and have not been independently verified by the publisher. The Company reports as a foreign private issuer on Form 20-F, which carries different periodic reporting obligations than those applying to a domestic United States filer. Filings are available on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca.
Cautionary Note Regarding Technology and Platform Claims: Descriptions of HYFT® Technology, ReefIQ™ and LensAI™, including pattern and relationship counts, curation history, product capabilities and the existence of contracted, recurring arrangements with life-sciences customers, are as described by the Company and have not been independently verified by the publisher. Those arrangements are not quantified, and specific customers, deployment counts and contract values have not been disclosed. Statements regarding platform adoption, commercial arrangements and future development are forward-looking and are not assurances of commercial outcomes. Patent applications are applications and may not be granted. Nothing in this article should be read as a claim of therapeutic benefit, efficacy or regulatory approval in respect of any product or program.
Cautionary Note Regarding Third-Party Technology References: References in this article to AMD, AMD Instinct or related architecture are paraphrased from public disclosures and are not product claims made by MindWalk Holdings Corp. MindWalk’s participation in the AMD Instinct demo showcase at Advancing AI 2026 was as a selected featured exhibitor. References to AMD do not imply endorsement, sponsorship, partnership or any commercial relationship beyond that selection.
Cautionary Note Regarding Referenced Companies: References to Veeva Systems Inc., Illumina, Inc., Certara, Inc. and Recursion Pharmaceuticals, Inc. are provided solely as market and sector context. None of them is a peer, competitor, or financial comparable of MindWalk Holdings Corp. They are at materially different stages of development and scale, several of them by orders of magnitude, and their revenues, margins, guidance, earnings and share performance are not indicative of MindWalk Holdings Corp.’s prospects. Nothing in this article suggests that MindWalk Holdings Corp. will achieve comparable results, and any grouping of these companies in this article is thematic rather than financial. None of the companies named has any involvement in MindWalk Holdings Corp., this article, or its distribution. No partnership, affiliation, sponsorship, or endorsement is implied.
Trademarks: HYFT® is a registered trademark of MindWalk Holdings Corp. ReefIQ™ and LensAI™ are trademarks of MindWalk Holdings Corp.; ReefIQ™ registration is pending. All other marks referenced in this article are the property of their respective owners.
Eagle Eye Disclosure: Eagle Eye is an investor signal-intelligence platform affiliated with the publisher of this article, and this reference constitutes promotion of an affiliated product. Eagle Eye is not a broker-dealer, and nothing in the platform or in this article is financial, investment, tax, or legal advice. Data provided in the platform is for informational purposes only and may be delayed. Always do your own research before making any investment decision.
Cautionary Note Regarding Forward-Looking Statements: This publication may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding platform commercialization, contracted and recurring arrangements, customer adoption, patent prosecution, operating expenses, financial condition and management’s plans and objectives. Such statements are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "believes", "intends", "potential" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual circumstances, events, or results to differ materially, including competitive, technological, commercial, financing, dilution, listing and market risks, and other risks identified in the Company’s filings with the Securities and Exchange Commission at www.sec.gov and on SEDAR+ at www.sedarplus.ca. Do not place undue reliance on such statements. The forward-looking statements in this publication are made as of the date above and Market Updates undertakes no obligation to update them.
Definitive Healthcare (NASDAQ:DH – Get Free Report) and Certara (NASDAQ:CERT – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, institutional ownership and valuation.
Insider & Institutional Ownership 98.7% of Definitive Healthcare shares are owned by institutional investors. Comparatively, 74.0% of Certara shares are owned by institutional investors. 17.1% of Definitive Healthcare shares are owned by insiders. Comparatively, 1.1% of Certara shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Risk and Volatility Definitive Healthcare has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Certara has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.
Analyst Recommendations This is a breakdown of recent recommendations and price targets for Definitive Healthcare and Certara, as provided by MarketBeat.com. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Definitive Healthcare 3 5 0 1 1.89 Certara 1 6 4 1 2.42 Definitive Healthcare currently has a consensus target price of $1.47, suggesting a potential upside of 63.08%. Certara has a consensus target price of $8.28, suggesting a potential upside of 2.19%. Given Definitive Healthcare’s higher possible upside, analysts clearly believe Definitive Healthcare is more favorable than Certara.
Valuation & Earnings This table compares Definitive Healthcare and Certara”s gross revenue, earnings per share and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Definitive Healthcare $241.52 million 0.40 -$138.93 million ($1.60) -0.56 Certara $418.84 million 2.95 -$1.60 million ($0.45) -18.00 Certara has higher revenue and earnings than Definitive Healthcare. Certara is trading at a lower price-to-earnings ratio than Definitive Healthcare, indicating that it is currently the more affordable of the two stocks.
Profitability This table compares Definitive Healthcare and Certara’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Definitive Healthcare -72.28% 3.55% 1.63% Certara -16.75% 3.86% 2.65% Summary Certara beats Definitive Healthcare on 9 of the 13 factors compared between the two stocks.
(Get Free Report)
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution. The company's platform consists of various functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. It serves biopharmaceutical and medical device companies, healthcare information technology companies, and healthcare providers; and other diversified companies comprising staffing and commercial real estate firms, financial institutions, and other organizations in the healthcare ecosystem. Definitive Healthcare Corp. was founded in 2011 and is headquartered in Framingham, Massachusetts.
About Certara (Get Free Report)
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Receive News & Ratings for Definitive Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definitive Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
BlackRock Inc. purchased a new position in shares of Certara, Inc. (NASDAQ:CERT – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 18,818,180 shares of the company’s stock, valued at approximately $123,259,000. BlackRock Inc. owned about 12.34% of Certara at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in the business. AQR Capital Management LLC bought a new position in shares of Certara in the 1st quarter valued at about $259,000. Goldman Sachs Group Inc. raised its stake in Certara by 65.6% in the first quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock worth $2,267,000 after buying an additional 90,724 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Certara by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock worth $2,965,000 after buying an additional 35,954 shares during the last quarter. Jane Street Group LLC increased its position in Certara by 17.1% during the 1st quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock valued at $2,743,000 after buying an additional 40,463 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Certara by 29.3% during the second quarter. JPMorgan Chase & Co. now owns 93,057 shares of the company’s stock worth $1,089,000 after buying an additional 21,099 shares during the period. 73.96% of the stock is currently owned by hedge funds and other institutional investors.
Certara Trading Down 0.7% Shares of Certara stock opened at $8.35 on Friday. Certara, Inc. has a fifty-two week low of $4.45 and a fifty-two week high of $13.88. The business’s fifty day moving average is $7.37 and its two-hundred day moving average is $6.47. The firm has a market cap of $1.27 billion, a PE ratio of -18.56 and a beta of 1.44. The company has a quick ratio of 2.55, a current ratio of 2.55 and a debt-to-equity ratio of 0.30.
Certara (NASDAQ:CERT – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.The firm had revenue of $93.27 million during the quarter, compared to analysts’ expectations of $98.09 million. During the same quarter last year, the business earned $0.07 earnings per share. The business’s revenue for the quarter was down 10.8% compared to the same quarter last year. Analysts anticipate that Certara, Inc. will post 0.22 earnings per share for the current year. Analyst Ratings Changes Several equities analysts have recently weighed in on CERT shares. Craig Hallum cut their target price on shares of Certara from $10.00 to $8.00 and set a “hold” rating for the company in a report on Tuesday, May 12th. Barclays upped their price target on Certara from $6.50 to $7.50 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. BMO Capital Markets cut their target price on shares of Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Tuesday, May 12th. Weiss Ratings upgraded shares of Certara from a “sell (e+)” rating to a “sell (d)” rating in a research note on Wednesday, August 5th. Finally, Morgan Stanley cut their target price on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Certara presently has an average rating of “Hold” and an average target price of $8.28.
Get Our Latest Analysis on CERT
Certara Profile (Free Report)
Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.
The company’s offerings are divided into software tools and consulting services.
Featured Stories Five stocks we like better than Certara 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude? Okta Stock Surges 29%—Is $200 the Next Stop? Want to see what other hedge funds are holding CERT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Certara, Inc. (NASDAQ:CERT – Free Report).
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.
Certara, Inc. (CERT - Free Report) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -20.00%. A quarter ago, it was expected that this company would post earnings of $0.11 per share when it actually produced earnings of $0.09, delivering a surprise of -18.18%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Certara, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $93.27 million for the quarter ended June 2026, missing the Zacks Consensus Estimate by 5.71%. This compares to year-ago revenues of $104.57 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Certara shares have lost about 7.2% since the beginning of the year versus the S&P 500's gain of 11%.
What's Next for Certara?While Certara has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Certara was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.10 on $95.44 million in revenues for the coming quarter and $0.38 on $399.62 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, InflaRx N.V. (IFRX - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on August 6.
This company is expected to post quarterly loss of $0.08 per share in its upcoming report, which represents a year-over-year change of +66.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
InflaRx N.V.'s revenues are expected to be $0.01 million, down 80% from the year-ago quarter.
3 Momentum Stocks That Could Soar Post-Market VolatilityCertara NASDAQ: CERT reported second-quarter 2026 revenue of $93.3 million, up 1% year over year, as software growth offset a decline in services revenue. Management reaffirmed its full-year revenue outlook while outlining further changes to its commercial organization, cost structure and artificial intelligence strategy.
Chief Executive Officer Jon Resnick said the quarter was focused on executing the company’s plan to build a business capable of sustainable double-digit growth. He said Certara’s market backdrop remains favorable, citing biopharma spending, clinical trial starts and regulatory guidance supporting model-informed drug development.
Get Certara alerts:
Software Growth Offsets Services Decline Simulations Plus Stock Drops 15% Despite EPS BeatSoftware revenue rose 4% year over year to $48.8 million, driven by Simcyp, Phoenix and Pinnacle 21. Software bookings increased 9% to $50.7 million, while trailing 12-month software bookings rose 8% to $196.4 million. Resnick said that, excluding the Chemaxon acquisition, trailing 12-month software bookings growth reached 7% exiting the first half, compared with 0.8% exiting 2025.
Software represented 53% of Certara’s business during the quarter, compared with 40% two years earlier, according to Resnick. The company also reported 30 Phoenix cloud implementations so far this year and cited international expansion, including its first major Simcyp win in China, broader activity in the Middle East and a modeling collaboration in Japan.
Are These 3 Small Momentum Stocks Setting Up Big Gains?Services revenue declined 3% to $44.5 million, while services bookings fell 6% to $47.6 million. The services business recorded a book-to-bill ratio of 1.07. Resnick said bookings were affected partly by the carve-out of the Regulatory and Medical Writing business, while Certara also began revising its broader services go-to-market approach.
Management pointed to a 27% year-over-year increase in the services pipeline exiting the quarter as a positive leading indicator. During the question-and-answer session, Resnick said the largest improvement in pipeline has come from services after the company moved away from a more generalist sales model and placed greater emphasis on specialist scientific engagements and PhD-led commercial teams.
Divestiture, Cost Actions and Commercial Changes Interim Chief Financial Officer Faiz Mohammed said Certara’s continuing-operations results include final adjustments related to the divestiture of its Regulatory and Medical Writing business. Through the May 8 closing date, that business contributed $19.2 million in revenue and $7.5 million in adjusted EBITDA, both reported as discontinued operations.
Certara implemented a reduction in force in May that primarily affected overhead positions and represented about 5% of its global workforce. Resnick said the action, along with other operational-excellence measures, is expected to generate approximately $13 million in run-rate savings. The company said the savings are intended to address stranded costs following the divestiture and support investments in innovation.
The company also reorganized around two business units: Model Informed Discovery and Drug Development, or MID3, and Accelerated Clinical Evidence, or ACE. Resnick said the structure is designed to align the organization with how clients consume Certara’s products and services.
Certara appointed Julien Perrier as chief commercial officer effective Aug. 1. Perrier previously led an AI-powered diagnostic company and has nearly two decades of international commercial leadership experience in biopharma, technology-enabled scientific services and AI-driven biotechnology, Resnick said. The company also promoted Eric Jahn to chief information officer.
Resnick described the commercial transformation as still being in its early stages. He said changes to the model began taking effect in the second quarter and were fully rolled out in July. The company is integrating sales and marketing around its business units, with an emphasis on data-driven and segment-focused commercial activity.
Profitability, Cash and Capital Allocation Second-quarter adjusted EBITDA was $26.2 million, down from $27 million a year earlier, and adjusted EBITDA margin was 28.1%. Mohammed attributed the margin decline largely to stranded costs associated with the divestiture.
Certara recorded a net loss from continuing operations of $6.1 million, compared with income from continuing operations of $1.5 million in the prior-year quarter. Mohammed said the change reflected the absence of a $5.7 million favorable contingent-consideration adjustment recorded a year earlier, a $2.9 million unfavorable change in currency expense and a $2.2 million increase in reorganization costs, partly offset by lower income tax expense.
Adjusted net income was $12.5 million, compared with $12.7 million a year earlier. Adjusted diluted earnings per share was $0.08, unchanged from the prior-year period. Cash and cash equivalents totaled $184.1 million at June 30. Outstanding term-loan borrowings were $294 million, and the company had $100 million available under its revolving credit facility. During the second quarter, Certara repurchased $17.4 million of stock, completing its previously authorized $100 million repurchase program. The board subsequently approved a new $50 million repurchase authorization. Resnick said the company had not established a timeline or specific execution plan for the new authorization.
Outlook and AI Initiatives Certara reaffirmed its outlook for 2026 revenue growth of 0% to 4%, representing revenue of $367 million to $382 million on a comparable continuing-operations basis. Management expects software revenue growth to be at or above the high end of that range, while services growth is expected to be at or below the low end.
The company now expects adjusted EBITDA margin of 29% to 31% for the year, compared with its prior 30% to 32% range. Mohammed said the revision reflects the divestiture’s effect on business mix and remaining shared infrastructure costs rather than underlying performance in the continuing business. Certara expects adjusted diluted EPS from continuing operations of $0.31 to $0.36, based on 155 million to 157 million fully diluted shares and an effective tax rate of about 30%.
Management also highlighted AI-related product and operational efforts. Resnick said up to 85% of newly developed code is AI-assisted, while the rate of development per software engineer has increased 65% year over year. He said internal AI agents have reduced cycle times by as much as 90% in some legal and IT workflows.
On the customer side, Certara is integrating D360 and Chemaxon Design Hub and plans for its next-generation platform to work alongside frontier AI models, including NVIDIA’s BioNeMo agent toolkit. Resnick said CoAuthor now includes nearly 600 AI agents and has delivered a 40% productivity increase in drafting quality-control documents, with more than 90% accuracy in summarizing complex data tables.
Resnick said Certara views its scientific expertise as an accountability layer for AI use in regulated settings, with scientists remaining responsible for decisions made in scientific-services workflows.
About Certara (NASDAQ:CERT)Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company's platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.
The company's offerings are divided into software tools and consulting services.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Certara Right Now?Before you consider Certara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list.
While Certara currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program
Reaffirms 2026 revenue guidance
RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its second quarter 2026 financial results.
Second Quarter Highlights from Continuing Operations:
Financial results of the Regulatory and Medical Writing business are reported as discontinued operations. The discussion in this earnings release presents the results of continuing operations and excludes amounts related to discontinued operations for all periods presented, unless otherwise noted.
Revenue was $93.3 million, compared to $92.4 million in the second quarter of 2025, representing growth of 1%.
Software revenue was $48.8 million, compared to $46.7 million in the second quarter of 2025, representing growth of 4%.Services revenue was $44.5 million, compared to $45.7 million in the second quarter of 2025, representing a decrease of 3%. Net loss was $6.1 million, compared to a net income of $1.5 million in the second quarter of 2025.
The change primarily reflects the absence of a $5.7 million favorable contingent consideration adjustment recorded in the prior-year period, a $2.9 million unfavorable swing in currency expense, and a $2.2 million increase in reorganization costs, partially offset by lower income tax expense. Adjusted EBITDA was $26.2 million, compared to $27.0 million in the second quarter of 2025, representing a decrease of 3%. “This second quarter was about continuing to execute on our commitments. Overall, we are pleased with our ongoing progress transforming Certara into a company we believe can deliver sustainable double-digit growth,” said Jon Resnick, Chief Executive Officer. “We completed the divestiture of our Regulatory and Medical Writing business, implemented our two new business units, and taken necessary actions to strengthen our leadership team and our commercial model. Our focus in the second half of the year is customer impact and speed of execution.”
“Our second quarter results were in line with our expectations, and we remain focused on executing against our full-year plan,” said Faiz Mohammed, Interim Chief Financial Officer. “We continue to expect full-year revenue growth of 0% to 4% on a comparable continuing operations basis, supported by continued strength in software and improving services performance as we move through the second half of the year.”
Second Quarter 2026 and Recent Corporate Updates
In May, Certara closed the divestiture of its global medical writing and related regulatory services business (“the Regulatory and Medical Writing business”) and announced the reorganization of its company around two business units, Model Informed Discovery and Drug Development (MID3) and Accelerated Clinical Evidence (ACE).In parallel with the reorganization, during the second quarter, Certara executed a reduction in force, focusing predominantly on overhead, impacting approximately 5% of its global employee base. This action, combined with other steps towards operational excellence, is expected to result in a run-rate savings of approximately $13 million. These reductions allow the Company to accelerate innovation and growth and streamline the Company’s cost base, including stranded costs from the divestiture. Certara has appointed Julien Perrier Chief Commercial Officer, effective August 1, 2026. Mr. Perrier brings nearly two decades of international commercial leadership in the life sciences. Most recently, he served as Chief Executive Officer of Ziwig, where he led the commercial development of the AI-powered diagnostic EndoTest. Prior to Ziwig, Mr. Perrier served as a Vice President at IQVIA, Head of the Immunology division, France at AbbVie, and Head of Office Specialty Care Division at Sanofi. As part of Certara’s move to align sales and marketing under a unified commercial leadership model in support of the business units, Mr. Perrier will focus on deepening customer engagement, sharpening go-to-market execution, and ensuring Certara’s products and services deliver clear, demonstrable value to customers worldwide.Certara has appointed Eric Jahn as Chief Information Officer. Mr. Jahn previously served as Senior Vice President, IT. He joined Certara in 2022 and has helped scale the business globally by partnering with all functions as a strategic business partner. Prior to Certara, Mr. Jahn served as Vice President, IT Infrastructure at TIBCO Software and spent seven years at Rocket Software in various IT leadership roles. Second Quarter 2026 Results from Continuing Operations
Financial results of the Regulatory and Medical Writing business are reported as discontinued operations. The discussion in this earnings release presents the results of continuing operations and excludes amounts related to discontinued operations for all periods presented, unless otherwise noted. Refer to Note 4 "Divestiture and Discontinued Operation" in our Form 10-Q for the quarter ended June 30, 2026 for further details.
Total revenue for the second quarter of 2026 was $93.3 million, representing year-over-year growth of 1% on a reported basis. Software revenue for the second quarter of 2026 was $48.8 million, representing year-over-year growth of 4% on a reported basis. Services revenue for the second quarter of 2026 was $44.5 million, representing a year-over-year decrease of 3% on a reported basis.
Total Bookings for the second quarter of 2026 were $98.3 million, representing a year-over-year increase of 1%.
Software Bookings for the second quarter of 2026 were $50.7 million, representing a year-over-year increase of 9%.
Services Bookings for the second quarter of 2026 were $47.6 million, representing a year-over-year decrease of 6%.
Total cost of revenues for the second quarter of 2026 was $35.1 million, an increase of $0.8 million from $34.3 million in the second quarter of 2025. The increase in cost of revenues was primarily due to a $1.0 million increase in employee-related costs and a $0.9 million increase in professional and consulting expenses, partially offset by a decrease in equity-based compensation expense and other miscellaneous expenses.
Total operating expenses for the second quarter of 2026 were $58.3 million, which increased by $7.9 million from $50.4 million in the second quarter of 2025. Higher operating expenses were primarily attributable to a $5.7 million increase related to the remeasurement of the fair value of business acquisition contingent consideration, primarily due to the absence of a non-recurring favorable change recognized in the prior year that reduced expenses in that period, a $1.1 million increase in professional and consulting expenses, a $1.0 million increase in employee-related costs, a $0.8 million increase in depreciation expense, and a $0.6 million increase in executive recruiting expenses, partially offset by a decrease in equity-based compensation expense.
Net loss for the second quarter of 2026 was $6.1 million, compared to net income of $1.5 million in the second quarter of 2025. The $7.6 million increase in loss was primarily driven by higher operating expenses, including a $5.7 million increase related to the remeasurement of the fair value of acquisition-related contingent consideration, $1.1 million aggregate increase in executive recruiting and lease abandonment charges, increased total other expenses, and a higher cost of revenue, partially offset by lower tax expense and higher revenue.
Diluted loss per share for the second quarter of 2026 was $(0.04), as compared to diluted earnings per share of $0.01 for the second quarter of 2025.
Adjusted EBITDA for the second quarter of 2026 was $26.2 million compared to $27.0 million for the second quarter of 2025, a decrease of $0.8 million. See note (1) in the section titled “A Note on Non-GAAP Financial Measures” below for more information on adjusted EBITDA.
Adjusted net income for the second quarter of 2026 was $12.5 million compared to $12.7 million for the second quarter of 2025, a decrease of $0.2 million. Adjusted diluted earnings per share for the second quarter of 2026 was $0.08, compared to $0.08 for the second quarter of 2025. See note (2) in the section titled “A Note on Non-GAAP Financial Measures” below for more information on adjusted net income and adjusted diluted earnings per share.
THREE MONTHS ENDED
JUNE 30, SIX MONTHS ENDED
JUNE 30, 2026 2025 2026 2025 Key Financials(in millions, except per share data)
Revenue$93.3 $92.4 $187.4 $184.5 Software revenue$48.8 $46.7 $98.5 $93.1 Service revenue$44.5 $45.7 $88.8 $91.4 Total bookings$98.3 $97.4 $195.5 $195.7 Software bookings$50.7 $46.6 $99.4 $87.3 Services bookings$47.6 $50.8 $96.1 $108.4 Net income (loss)$(6.1) $1.5 $(17.9) $3.0 Diluted earnings (loss) per share$(0.04) $0.01 $(0.11) $0.02 Adjusted EBITDA$26.2 $27.0 $52.9 $55.4 Adjusted net income$12.5 $12.7 $21.6 $29.5 Adjusted diluted earnings per share$0.08 $0.08 $0.14 $0.18 Cash and cash equivalents $184.1 $162.3
2026 Financial Outlook
Certara is reaffirming its revenue growth and updating its adjusted EBITDA margin, adjusted diluted earnings per share, and fully diluted share guidance for the full year 2026, to reflect the divestiture of the Regulatory and Medical Writing business and Continuing Operations reporting:
Revenue growth for Continuing Operations, excluding the Regulatory and Medical Writing business, is expected to be 0% to 4%, or revenue of $367 million to $382 million.
Full year 2026 adjusted EBITDA margin for Continuing Operations, excluding the Regulatory and Medical writing business, is expected to be approximately 29% to 31%.
Full year adjusted diluted earnings per share for Continuing Operations, excluding the Regulatory and Medical Writing business is expected to be in the range of $0.31 to $0.36.
Fully diluted shares are expected to be in the range of 155 million to 157 million. Financial results of the Regulatory and Medical Writing business will be reported as discontinued operations for 2026. Through the transaction closing on May 8, 2026, the year-to-date discontinued operations Revenue was $19.2 million.
In the second quarter, the Company repurchased $17.4 million in shares, which completed a $100 million share repurchase program under terms previously authorized by the Board. In the third quarter, the Board approved an additional $50 million under the share repurchase program, reflecting the Company’s continued confidence in the business and its disciplined approach to capital allocation. The program does not have an express expiration date, and all repurchase plans must be brought in advance to the Board.
Please note that the Company has not reconciled adjusted EBITDA, adjusted EBITDA margin or adjusted diluted earnings per share forward-looking guidance included in this press release to the most directly comparable GAAP measures because this cannot be done without unreasonable effort due to the variability and low visibility with respect to costs related to acquisitions, financings, and employee stock compensation programs, which are potential adjustments to future earnings. The Company expects the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.
Webcast and Conference Call Details
Certara will host a conference call today, August 4, 2026, at 8:30 a.m. ET to discuss its second quarter 2026 financial results. Investors interested in listening to the conference call are required to register online in advance of the call. A live and archived webcast of the event will be available on the “Investors” section of the Certara website at https://ir.certara.com.
About Certara
Certara accelerates medicines using biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.
Please visit our website at www.certara.com. We intend to use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD.
Such disclosures will be included in the Investor Relations section of our website at https://ir.certara.com. Accordingly, investors should monitor such portion of our website, in addition to following our press releases, Securities and Exchange Commission filings and public conference calls and webcasts.
Forward-Looking Statements
This press release contains certain statements that constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, with respect to the Company’s full-year guidance. These statements typically contain words such as “believe,” “may,” “potential,” “will,” “plan,” “could,” “estimate,” “expects” and “anticipates” or the negative of these words or other similar terms or expressions. Any statement in this press release that is not a statement of historical fact is a forward-looking statement and involves significant risks and uncertainties. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot provide any assurance that these expectations will prove to be correct. You should not rely upon forward-looking statements as predictions of future events and actual results, events, or circumstances. Actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including our ability to realize the expected benefits of the divestiture of our regulatory and medical writing business; any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery and development; our ability to compete within our market; changes or delays in government regulation relating to the biopharmaceutical industry; trends in research and development spending; operational disruptions, funding constraints and policy changes at the Food and Drug Administration and other government agencies; consolidation within the biopharmaceutical industry; our ability to increase successfully our customer base, expand relationships and the products and services we provide and enter new markets; our ability to retain key personnel or recruit additional qualified personnel; risks related to the mischaracterization of our independent contractors; any delays or defects in our release of new or enhanced software or other biosimulation tools; issues relating to implementation, use and development of artificial intelligence and machine learning in our products and services; failure of our existing customers to renew their software licenses or any delays or terminations of contracts or reductions in scope of work by our existing customers; risks related to our contracts with government customers and receipt of government grants; risks related to any future acquisitions and other strategic transactions; the accuracy of our addressable market estimates; our ability to operate successfully a global business and adverse global economic conditions; our ability to comply with applicable trade compliance and economic sanctions laws and regulations; the impact of litigation; the sufficiency of our insurance coverage; our ability to perform our services in accordance with contractual requirements, regulatory standards and ethical considerations; the loss of more than one of our major customers; our ability to raise capital or generate sufficient cash flows; the ability or inability of our bookings to accurately predict our future revenue and our ability to realize the anticipated revenue reflected in our bookings; our ability to comply with anti-corruption laws; risks related to catastrophic events; the application of evolving corporate governance and public disclosure requirements; disruptions in the operations of the third-party providers who host our software solutions or any limitations on their capacity or interference with our use; any unauthorized access to or use of customer or other proprietary or confidential data or other breach of our cybersecurity measures, compliance with privacy and cybersecurity laws and related contractual requirements; our ability to reliably meet our data storage and management requirements, or the experience of any failures or interruptions in the delivery of our services over the internet; our ability to comply with the terms of any licenses governing our use of third-party open source software; our ability to adequately enforce or defend our ownership and use of our intellectual property and other proprietary rights; any allegations that we are infringing, misappropriating or otherwise violating a third party’s intellectual property rights; our ability to comply with healthcare laws; risks related to our indebtedness; any additional impairment of goodwill or other intangible assets; our ability to use net operating losses; the volatility of the market price of our common stock; future sales of our common stock by existing stockholders; the substantial holdings of our largest stockholder; and the other factors detailed under the captions “Risk Factors” and “Special Note Regarding Forward-Looking Statements” and elsewhere in our Securities and Exchange Commission (“SEC”) filings, and reports, including the Form 10-K filed by the Company with the Securities and Exchange Commission on February 26, 2026, and subsequent reports filed with the SEC. Any forward-looking statements speak only as of the date of this release and, except to the extent required by applicable securities laws, we expressly disclaim any obligation to update or revise any of them to reflect actual results, any changes in expectations or any change in events.
A Note on Non-GAAP Financial Measures
This press release contains “non-GAAP measures” which are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Specifically, the Company makes use of the non-GAAP financial measures adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss) and adjusted diluted earnings per share which are not recognized terms under GAAP. These measures should not be considered as alternatives to net income (loss), net income (loss) margin, or GAAP diluted earnings per share or revenue as measures of financial performance or any other performance measure derived in accordance with GAAP and should not be considered a measure of discretionary cash available to the Company to invest in the growth of its business. The presentation of these measures has limitations as an analytical tool and should not be considered in isolation, or as a substitute for the Company’s results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.
You should refer to the footnotes below as well as the “Reconciliation of Non-GAAP Financial Measures” section in this press release below for a further explanation of these measures and reconciliations of these non-GAAP measures in specific periods to their most directly comparable financial measure calculated and presented in accordance with GAAP for those periods.
Management uses various financial metrics, including total revenues, income (loss) from operations, net income (loss), and certain non-GAAP measures, such as adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss) and adjusted diluted earnings per share, to make budgeting decisions, to make certain compensation decisions, and to compare the Company’s performance against that of other peer companies using similar measures. In addition, management believes these metrics provide useful measures for period-to-period comparisons of the Company’s business, as they remove the effect of certain non-cash expenses and other items not indicative of its ongoing operating performance.
Management believes that adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss) and adjusted diluted earnings per share are helpful to investors, analysts, and other interested parties because they can assist in providing a more consistent and comparable overview of our operations across our historical periods. In addition, these non-GAAP measures are frequently used by analysts, investors, and other interested parties to evaluate and assess performance.
(1) Adjusted EBITDA represents net income (loss) excluding interest expense, provision for (benefit from) for income taxes, depreciation and amortization expense, intangible asset amortization, equity-based compensation expense, goodwill impairment, change in fair value of contingent consideration, acquisition and integration expense and other items not indicative of our ongoing operating performance. Adjusted EBITDA margin represents adjusted EBITDA divided by revenue.
(2) Adjusted net income and adjusted diluted earnings per share exclude the effect of equity-based compensation expense, amortization of acquisition-related intangible assets, goodwill impairment, change in fair value of contingent consideration, acquisition and integration expense, and other items not indicative of our ongoing operating performance as well as income tax provision adjustment for such charges.
In evaluating adjusted EBITDA, adjusted EBITDA margin, adjusted net income, and adjusted diluted earnings per share, you should be aware that in the future the Company may incur expenses similar to those eliminated in this presentation and this presentation should not be construed as an inference that future results will be unaffected by unusual items.
CERTARA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
THREE MONTHS ENDED
JUNE 30, SIX MONTHS ENDED
JUNE 30,(IN THOUSANDS, EXCEPT PER SHARE AND SHARE DATA) 2026 2025 2026 2025 Total revenue$93,271 $92,356 $187,363 $184,455 Cost of revenues 35,122 34,285 69,794 69,005 Operating expenses: Sales and marketing 14,978 13,658 27,928 26,044 Research and development 9,705 8,972 21,991 19,494 General and administrative 21,933 16,700 50,875 35,985 Depreciation and amortization 11,729 11,070 23,235 21,961 Total operating expenses 58,345 50,400 124,029 103,484 Income (loss) from operations (196) 7,671 (6,460) 11,966 Other income (expenses): Interest expense (4,987) (4,802) (9,928) (9,608)Net other income (expenses) (1,205) 1,501 96 3,226 Total other expenses (6,192) (3,301) (9,832) (6,382)Income (loss) before income taxes (6,388) 4,370 (16,292) 5,584 Provision (benefits) for income taxes on continuing operations (307) 2,874 1,614 2,583 income (loss) from continuing operations, net of tax (6,081) 1,496 (17,906) 3,001 Loss from discontinued operations, net of tax (49,189) (3,464) (46,127) (226)Net income (loss) attributable to common stockholders$(55,270) $(1,968) $(64,033) $2,775 Net income (loss) per share attributable to common stockholders: Basic - Earnings (loss) per common share from continuing operations$(0.04) $0.01 $(0.11) $0.02 Basic - Earnings (loss) per common share from discontinued operations$(0.32) $(0.02) $(0.30) $— Basic - Earnings (loss) per common share$(0.36) $(0.01) $(0.41) $0.02 Diluted - Earnings (loss) per common share from continuing operations$(0.04) $0.01 $(0.11) $0.02 Diluted - Earnings (loss) per common share from discontinued operations$(0.32) $(0.02) $(0.30) $— Diluted - Earnings (loss) per common share$(0.36) $(0.01) $(0.41) $0.02 Weighted average common shares outstanding: Basic 154,356,779 160,916,057 156,046,326 160,955,936 Diluted 154,356,779 161,849,002 156,046,326 161,601,024 CERTARA, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(UNAUDITED) (IN THOUSANDS, EXCEPT PER SHARE AND SHARE DATA) JUNE 30,
2026 DECEMBER 31,
2025Assets Current assets: Cash and cash equivalents $184,138 $189,392 Accounts receivable, net of allowances for credit losses of $1,940 and $2,235 100,759 101,574 Prepaid expenses and other current assets 27,289 21,887 Current assets of discontinued operations — 2,266 Total current assets 312,186 315,119 Other assets: Property and equipment, net 1,673 1,805 Operating lease right-of-use assets 8,952 11,840 Goodwill 718,125 745,056 Intangible assets, net of accumulated amortization of $345,829 and $415,804 345,207 361,835 Deferred income taxes 11,115 3,856 Other long-term assets 2,540 1,509 Other assets of discontinued operations — 115,562 Total assets $1,399,798 $1,556,582 Liabilities and stockholders' equity Current liabilities: Accounts payable $2,723 $3,040 Accrued expenses 36,211 59,658 Current portion of deferred revenue 77,341 75,398 Current portion of long-term debt 2,963 2,963 Other current liabilities 3,161 4,365 Current liabilities of discontinued operations — 7,961 Total current liabilities 122,399 153,385 Long-term liabilities: Deferred revenue, net of current portion 2,704 2,350 Deferred income taxes 8,947 34,366 Operating lease liabilities, net of current portion 6,945 8,438 Long-term debt, net of current portion and debt discount 288,876 290,131 Other long-term liabilities 3,412 5,117 Total liabilities 433,283 493,787 Commitments and contingencies Stockholders' equity Preferred shares, $0.01 par value, 50,000,000 shares authorized; no shares issued, and outstanding as of June 30, 2026 and December 31, 2025, respectively — — Common shares, $0.01 par value, 600,000,000 shares authorized, 166,959,761 and 164,005,450 shares issued as of June 30, 2026 and December 31, 2025; 152,499,023 and 159,139,562 shares outstanding as of June 30,2026 and December 31, 2025, respectively 1,671 1,641 Additional paid-in capital 1,277,660 1,255,653 Accumulated deficit (193,909) (129,876)Accumulated other comprehensive income 9,057 2,040 Treasury stock at cost, 14,460,738 and 4,865,888 shares at June 30, 2026 and December 31, 2025, respectively (127,964) (66,663)Total stockholders' equity 966,515 1,062,795 Total liabilities and stockholders' equity $1,399,798 $1,556,582 CERTARA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED) SIX MONTHS ENDED JUNE 30,(IN THOUSANDS) 2026 2025 Cash flows from operating activities: Net income (loss) from continuing operations $(17,906) $3,001 Adjustments to reconcile net income (loss) to net cash provided by operating activities: Depreciation and amortization 32,342 31,271 Amortization of debt issuance costs 270 289 Provision for credit losses (22) 401 Equity-based compensation expense 13,414 15,315 Change in fair value of contingent considerations 7,230 (5,901)Deferred income taxes (8,698) (1,969)Changes in assets and liabilities: Accounts receivable 8,231 5,575 Prepaid expenses and other assets (5,622) 5,873 Accounts payable, accrued expenses, and other liabilities (15,682) (19,487)Deferred revenues 2,041 (9,863)Other operating activities, net (14) (1,176)Cash provided by operating activities - continuing operations 15,584 23,329 Cash provided by operating activities - discontinued operations 6,148 11,865 Net cash provided by operating activities 21,732 35,194 Cash flows from investing activities: Capital expenditures (1,252) (536)Capitalized software development costs (13,223) (12,199)Cash used in investing activities - continuing operations (14,475) (12,735)Cash provided by investing activities - discontinued operations 69,435 — Net cash provided (used) in investing activities 54,960 (12,735)Cash flows from financing activities: Payments on long-term debt (1,481) (1,500)Common stock repurchase program (57,389) (25,000)Payments for business acquisition related contingent consideration (20,121) (13,230)Payment of taxes on shares withheld for employee taxes (3,339) (4,960)Net cash used in financing activities (82,330) (44,690)Effect of foreign exchange rate on cash and cash equivalents 384 5,314 Net decrease in cash and cash equivalents (5,254) (16,917)Cash and cash equivalents at beginning of period 189,392 179,183 Cash and cash equivalents at end of period $184,138 $162,266 NON-GAAP FINANCIAL MEASURES
The following table reconciles net income (loss) from continuing operations to Adjusted EBITDA:
THREE MONTHS ENDED
JUNE 30, SIX MONTHS ENDED
JUNE 30, 2026 2025 2026 2025 (in thousands)Net income (loss) from continuing operations(a)$(6,081) $1,496 $(17,906) $3,001 Interest expense(a) 4,987 4,802 9,928 9,608 Interest income(a) (943) (1,243) (2,069) (2,885)(Benefit from) Provision for income taxes(a) (307) 2,874 1,614 2,583 Intangible asset amortization and fixed assets depreciation(a) 16,329 15,733 32,342 31,271 Currency (gain) loss(a) 2,358 (577) 2,418 (639)Equity-based compensation expense(b) 6,094 8,245 13,414 15,315 Change in fair value of contingent consideration(d) — (5,722) 7,230 (5,901)Acquisition-related (income) expenses(e) (132) 428 (114) 1,304 Reorganization expense(f) 3,182 934 4,187 1,085 Loss (gain) on disposal of fixed assets(g) (24) (1) (14) 5 Executive recruiting expense(h) 735 — 1,851 661 Adjusted EBITDA$26,198 $26,969 $52,881 $55,408
The following table reconciles net income (loss) from continuing operations to adjusted net income:
THREE MONTHS ENDED
JUNE 30, SIX MONTHS ENDED
JUNE 30, 2026 2025 2026 2025 ( in thousands)Net income (loss) from continuing operations(a)$(6,081) $1,496 $(17,906) $3,001 Currency (gain) loss(a) 2,358 (577) 2,418 (639)Equity-based compensation expense(b) 6,094 8,245 13,414 15,315 Amortization of acquisition-related intangible assets(c) 10,849 10,947 21,640 21,938 Change in fair value of contingent consideration(d) — (5,722) 7,230 (5,901)Acquisition-related (income) expenses(e) (132) 428 (114) 1,304 Reorganization expense(f) 3,182 934 4,187 1,085 Loss (gain) on disposal of fixed assets(g) (24) (1) (14) 5 Executive recruiting expense(h) 735 — 1,851 661 Income tax expense impact of adjustments(i) (4,441) (3,023) (11,132) (7,319) Adjusted net income$12,540 $12,727 $21,574 $29,450
The following tables reconciles diluted earnings per share from continuing operations to adjusted diluted earnings per share:
THREE MONTHS ENDED
JUNE 30, SIX MONTHS ENDED
JUNE 30, 2026 2025 2026 2025 Diluted earnings per share from continuing operations (a)$(0.04) $0.01 $(0.11) $0.02 Currency (gain) loss(a) 0.02 - 0.02 - Equity-based compensation expense(b) 0.04 0.05 0.08 0.09 Amortization of acquisition-related intangible assets(c) 0.07 0.07 0.13 0.14 Change in fair value of contingent consideration(d) - (0.04) 0.05 (0.04)Acquisition-related expenses(e) - - - 0.01 Reorganization expense(f) 0.02 0.01 0.03 0.01 Loss (gain) on disposal of fixed assets(g) - - - - Executive recruiting expense(h) - - 0.01 - Income tax expense impact of adjustments(i) (0.03) (0.02) (0.07) (0.05) Adjusted diluted earnings per share$0.08 $0.08 $0.14 $0.18 Basic weighted average common shares outstanding 154,356,779 160,916,057 156,046,326 160,955,936 Effect of potentially dilutive shares outstanding (j) 595,507 932,945 433,412 645,088 Adjusted diluted weighted average common shares outstanding 154,952,286 161,849,002 156,479,738 161,601,024
(a) Represents a measure determined under GAAP.
(b) Represents expense related to equity-based compensation. Equity-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.
(c) Represents amortization costs associated with acquired intangible assets in connection with business acquisitions.
(d) Represents expense associated with fair value adjustment or adjustment of contingent consideration of business acquisition.
(e) Represents costs associated with mergers and acquisitions and any retention bonuses pursuant to the acquisitions.
(f) Represents expenses related to reorganization, including legal entity reorganization and lease abandonment costs associated with the evaluation of our office space footprint.
(g) Represents the gain/loss related to disposal of fixed assets.
(h) Represents recruiting, relocation expenses, and retention costs related to senior executives.
(i) Represents the income tax effect of the non-GAAP adjustments calculated using the applicable statutory rate by jurisdiction.
(j) Represents potentially dilutive shares that were included from our GAAP diluted weighted average common shares outstanding.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Certara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara said that it saw "softer performance from Tier 1 customers in MIDD services" and that services performance was "mixed." The Company also announced its exit from the regulatory business in their service segment. I n response to a question about consistency between software and services performance, Certara said that there had been "a lot of inconsistency and back and forth" over the last few quarters.
On this news, Certara's stock price fell $1.18 per share, or approximately 19%, to close at $5.13 on May 11, 2026.
Then, on June 17, 2026, Certara announced that John Gallagher, the Company's Chief Financial Officer, had notified Certara of his intent to resign from his office effective as of the end of the day on July 14, 2026.
On this news, Certara's stock price fell $0.49 per share, or 8.13%, to close at $5.54 per share on June 18, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Certara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara said that it saw “softer performance from Tier 1 customers in MIDD services” and that services performance was “mixed.” The Company also announced its exit from the regulatory business in their service segment. I n response to a question about consistency between software and services performance, Certara said that there had been “a lot of inconsistency and back and forth” over the last few quarters.
On this news, Certara’s stock price fell $1.18 per share, or approximately 19%, to close at $5.13 on May 11, 2026.
Then, on June 17, 2026, Certara announced that John Gallagher, the Company’s Chief Financial Officer, had notified Certara of his intent to resign from his office effective as of the end of the day on July 14, 2026.
On this news, Certara’s stock price fell $0.49 per share, or 8.13%, to close at $5.54 per share on June 18, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Certara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara said that it saw "softer performance from Tier 1 customers in MIDD services" and that services performance was "mixed." The Company also announced its exit from the regulatory business in their service segment. I n response to a question about consistency between software and services performance, Certara said that there had been "a lot of inconsistency and back and forth" over the last few quarters.
On this news, Certara's stock price fell $1.18 per share, or approximately 19%, to close at $5.13 on May 11, 2026.
Then, on June 17, 2026, Certara announced that John Gallagher, the Company's Chief Financial Officer, had notified Certara of his intent to resign from his office effective as of the end of the day on July 14, 2026.
On this news, Certara's stock price fell $0.49 per share, or 8.13%, to close at $5.54 per share on June 18, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
RADNOR, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2026 before market open on Tuesday, August 4th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET.
Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance.
A live and archived webcast of the event will be available on the “Investors” section of the Certara website at https://ir.certara.com/.
About Certara
Certara transforms drug discovery and development for good, helping scientists and clinical teams generate regulatory-grade evidence faster. Its solutions combine biosimulation, clinical intelligence, and regulatory science, and are embedded in the workflows of drug developers worldwide. Certara clients include more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies. Learn more at certara.com.
Investor Relations Contact:
Erik Abdow
Gilmartin Group [email protected]
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Certara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara said that it saw “softer performance from Tier 1 customers in MIDD services” and that services performance was “mixed.” The Company also announced its exit from the regulatory business in their service segment. I n response to a question about consistency between software and services performance, Certara said that there had been “a lot of inconsistency and back and forth” over the last few quarters.
On this news, Certara’s stock price fell $1.18 per share, or approximately 19%, to close at $5.13 on May 11, 2026.
Then, on June 17, 2026, Certara announced that John Gallagher, the Company’s Chief Financial Officer, had notified Certara of his intent to resign from his office effective as of the end of the day on July 14, 2026.
On this news, Certara’s stock price fell $0.49 per share, or 8.13%, to close at $5.54 per share on June 18, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Certara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara said that it saw "softer performance from Tier 1 customers in MIDD services" and that services performance was "mixed." The Company also announced its exit from the regulatory business in their service segment. I n response to a question about consistency between software and services performance, Certara said that there had been "a lot of inconsistency and back and forth" over the last few quarters.
On this news, Certara's stock price fell $1.18 per share, or approximately 19%, to close at $5.13 on May 11, 2026.
Then, on June 17, 2026, Certara announced that John Gallagher, the Company's Chief Financial Officer, had notified Certara of his intent to resign from his office effective as of the end of the day on July 14, 2026.
On this news, Certara's stock price fell $0.49 per share, or 8.13%, to close at $5.54 per share on June 18, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Certara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara said that it saw “softer performance from Tier 1 customers in MIDD services” and that services performance was “mixed.” The Company also announced its exit from the regulatory business in their service segment. I n response to a question about consistency between software and services performance, Certara said that there had been “a lot of inconsistency and back and forth” over the last few quarters.
On this news, Certara’s stock price fell $1.18 per share, or approximately 19%, to close at $5.13 on May 11, 2026.
Then, on June 17, 2026, Certara announced that John Gallagher, the Company’s Chief Financial Officer, had notified Certara of his intent to resign from his office effective as of the end of the day on July 14, 2026.
On this news, Certara’s stock price fell $0.49 per share, or 8.13%, to close at $5.54 per share on June 18, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
New capabilities unify Certara's biosimulation software, products, datasets, and scientific expertise with AI-driven agents to deliver specialized insights for life sciences July 07, 2026 08:00 ET | Source: Certara
RADNOR, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, is partnering with NVIDIA to advance Certara's open integrated AI platform, unifying its scientific software, regulatory expertise, and proprietary datasets with AI-first, agentic frameworks.
The NVIDIA BioNeMo Agent Toolkit turns any AI agent into an autonomous life sciences scientist, providing access to NVIDIA’s full life science stack. Within Certara's platform, BioNeMo Agent Toolkit serves as one of several agentic frameworks available to clients, working alongside Certara's biosimulation models, regulatory expertise, and scientific teams to accelerate insight generation.
“Agentic AI combined with Certara's world-class scientists, validated models, and data keeps the scientist in the loop while delivering the speed, scale, and reproducibility our clients need to generate integrated evidence for regulators,” said Jon Resnick, Chief Executive Officer. “Our collaboration with NVIDIA intends to bring frontier AI to life sciences responsibly, at scale, and with the scientific rigor the industry demands.”
Specialized AI agents will reason over Certara's scientific models, data, and domain expertise to produce insights across the full development continuum — optimizing a dosing strategy with systems pharmacology models, interrogating a clinical dataset, simulating patient and trial scenarios, evaluating ADMET properties, assembling regulatory-ready evidence, and exploring early discovery hypotheses. Agentic AI augments biosimulation experts and scientific teams, delivering faster access to insights while keeping scientists at the center of decision-making.
“We believe it will become increasingly possible to computationally simulate human biology in ways that will transform the discovery and development of new medicines,” said Chris Bouton, Chief Technology Officer, Chief AI Officer. “Our collaboration with NVIDIA and addition of the BioNeMo Agent Toolkit to the integrated platform helps accelerate that vision.”
About Certara
Certara transforms drug discovery and development for good, helping scientists and clinical teams generate regulatory-grade evidence faster. Its solutions combine biosimulation, clinical intelligence, and regulatory science, and are embedded in the workflows of drug developers worldwide. Certara clients include more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies. Learn more at certara.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding Certara’s integrated platform, the collaboration with NVIDIA, the integration of NVIDIA BioNeMo Agent Toolkit, and the anticipated benefits, capabilities, availability, and impact of these technologies. These statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Certara undertakes no obligation to update any forward-looking statement except as required by law.
Investor Relations Contact:
David Deuchler
Gilmartin Group [email protected]
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Certara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara said that it saw “softer performance from Tier 1 customers in MIDD services” and that services performance was “mixed.” The Company also announced its exit from the regulatory business in their service segment. I n response to a question about consistency between software and services performance, Certara said that there had been “a lot of inconsistency and back and forth” over the last few quarters.
On this news, Certara’s stock price fell $1.18 per share, or approximately 19%, to close at $5.13 on May 11, 2026.
Then, on June 17, 2026, Certara announced that John Gallagher, the Company’s Chief Financial Officer, had notified Certara of his intent to resign from his office effective as of the end of the day on July 14, 2026.
On this news, Certara’s stock price fell $0.49 per share, or 8.13%, to close at $5.54 per share on June 18, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Certara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara said that it saw "softer performance from Tier 1 customers in MIDD services" and that services performance was "mixed." The Company also announced its exit from the regulatory business in their service segment. I n response to a question about consistency between software and services performance, Certara said that there had been "a lot of inconsistency and back and forth" over the last few quarters.
On this news, Certara's stock price fell $1.18 per share, or approximately 19%, to close at $5.13 on May 11, 2026.
Then, on June 17, 2026, Certara announced that John Gallagher, the Company's Chief Financial Officer, had notified Certara of his intent to resign from his office effective as of the end of the day on July 14, 2026.
On this news, Certara's stock price fell $0.49 per share, or 8.13%, to close at $5.54 per share on June 18, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Reaffirms 2026 Guidance June 17, 2026 16:30 ET | Source: Certara
RADNOR, Pa., June 17, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, announces that John Gallagher, Chief Financial Officer, has notified the Company of his intent to resign from his office effective as of the end of the day on July 14, 2026.
Concurrently, Certara has launched a search with a leading executive search firm to identify the Company's next Chief Financial Officer.
Faiz Mohammed, Certara's Senior Vice President of Finance and Treasurer, has agreed to serve as Interim CFO upon Mr. Gallagher's departure until a successor is named and appointed. Mr. Mohammed has been a finance leader with Certara since 2018 and brings more than 25 years of senior finance and accounting experience across public and private equity-backed companies.
Certara Reaffirms 2026 Guidance
Certara takes this opportunity to reaffirm the Company’s 2026 Financial Guidance provided during the first quarter earnings call on May 11, 2026.
About Certara
Certara transforms drug discovery and development for good, helping scientists and clinical teams generate regulatory-grade evidence faster. Its solutions combine biosimulation, clinical intelligence, and regulatory science, and are embedded in the workflows of drug developers worldwide. Certara clients include more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies. Learn more at certara.com.
Investor Relations Contact:
David Deuchler
Gilmartin Group [email protected]
Forward Looking Statements
This press release contains certain statements that constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the Company’s financial guidance, management succession plans and future business and financial performance and outlook. Actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including disruption from the recently completed divestiture of our Regulatory Medical Writing business transaction making it more difficult to maintain business and operational relationships; any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery and development; our ability to compete within our market; changes or delays in government regulation relating to the biopharmaceutical industry; trends in research and development spending; operational disruptions, funding constraints and policy changes at the Food and Drug Administration and other government agencies; consolidation within the biopharmaceutical industry; our ability to increase successfully our customer base, expand relationships and the products and services we provide and enter new markets; our ability to retain key personnel or recruit additional qualified personnel; risks related to the mischaracterization of our independent contractors; any delays or defects in our release of new or enhanced software or other biosimulation tools; issues relating to implementation, use and development of artificial intelligence and machine learning in our products and services; failure of our existing customers to renew their software licenses or any delays or terminations of contracts or reductions in scope of work by our existing customers; risks related to our contracts with government customers and receipt of government grants; risks related to any future acquisitions and other strategic transactions; the accuracy of our addressable market estimates; our ability to operate successfully a global business and adverse global economic conditions; our ability to comply with applicable trade compliance and economic sanctions laws and regulations; the impact of litigation; the sufficiency of our insurance coverage; our ability to perform our services in accordance with contractual requirements, regulatory standards and ethical considerations; the loss of more than one of our major customers; our ability to raise capital or generate sufficient cash flows; the ability or inability of our bookings to accurately predict our future revenue and our ability to realize the anticipated revenue reflected in our; our ability to comply with anti-corruption laws; risks related to catastrophic events; the application of evolving corporate governance and public disclosure requirements; disruptions in the operations of the third-party providers who host our software solutions or any limitations on their capacity or interference with our use; any unauthorized access to or use of customer or other proprietary or confidential data or other breach of our cybersecurity measures, compliance with privacy and cybersecurity laws and related contractual requirements; our ability to reliably meet our data storage and management requirements, or the experience of any failures or interruptions in the delivery of our services over the internet; our ability to comply with the terms of any licenses governing our use of third-party open source software; our ability to adequately enforce or defend our ownership and use of our intellectual property and other proprietary rights; any allegations that we are infringing, misappropriating or otherwise violating a third party’s intellectual property rights; our ability to comply with healthcare laws; risks related to our indebtedness; any additional impairment of goodwill or other intangible assets; our ability to use net operating losses; the volatility of the market price of our common stock; future sales of our common stock by existing stockholders; the substantial holdings of our largest stockholder; and the other factors detailed under the captions “Risk Factors” and “Special Note Regarding Forward-Looking Statements” and elsewhere in our Securities and Exchange Commission (“SEC”) filings, and reports, including the Form 10-K filed by the Company with the Securities and Exchange Commission on February 26, 2026, and subsequent reports filed with the SEC. Any forward-looking statements speak only as of the date of this release and, except to the extent required by applicable securities laws, we expressly disclaim any obligation to update or revise any of them to reflect actual results, any changes in expectations or any change in events.
SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Certara, Inc. (NASDAQ: CERT). The investigation focuses on Certara’s executive officers and whether investor losses may be recovered under federal securities laws.
What if I purchased Certara securities?
If you purchased Certara securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.
Or for more information, contact Jim Baker at [email protected] or (619) 814-4471.
There is no cost or obligation to you.
Background of the investigation
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara stated that it saw “softer performance from Tier 1 customers in MIDD services” and that services performance was “mixed.” The Company also discussed execution and go-to-market challenges in its services business and stated, in response to a question about consistency between software and services performance, that there had been “a lot of inconsistency and back and forth” over the last few quarters.
Following this news, Certara’s stock price declined sharply, damaging investors.
Then, on June 17, 2026, Certara announced a Chief Financial Officer transition, disclosing that John Gallagher, the Company’s Chief Financial Officer, had notified Certara of his intent to resign effective as of the end of the day on July 14, 2026. Certara also announced that Faiz Mohammed, the Company’s Senior Vice President of Finance and Treasurer, would serve as Interim Chief Financial Officer following Mr. Gallagher’s departure while the Company searches for a permanent successor.
In light of this disclosure, Johnson Fistel is investigating whether Certara complied with the federal securities laws. If you suffered losses from your investment in Certara stock, contact Johnson Fistel.
About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit www.johnsonfistel.com.
Achievements
In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm’s effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Contact
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471 | [email protected]
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Certara (CERT) To Contact Him Directly To Discuss Their Options
If you purchased or acquired stock in Certara and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, June 19, 2026 (GLOBE NEWSWIRE) --
What’s Happening:
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT) on behalf of Certara stockholders. Our investigation concerns whether Certara has violated the federal securities laws and/or engaged in other unlawful business practices.
Investigation Details:
On May 11, 2026, Certara announced its financial results for the first quarter of 2026. Among other disclosures, the Company reported that services revenue declined 4% year over year to $57.2 million, while services bookings decreased 14% year over year to $66.6 million. In discussing the quarter, Certara stated that it experienced “softer performance from Tier 1 customers in MIDD services” and described services performance as “mixed.” The Company also announced its exit from the regulatory business within its services segment. In response to a question regarding consistency between software and services performance, the Company stated that there had been “a lot of inconsistency and back and forth” over the last several quarters. Following this news, the price of Certara shares fell by $1.18 per share, or approximately 19%, declining from $6.31 per share on May 8, 2026 to close at $5.13 per share on May 11, 2026.
Next Steps:
If you purchased or otherwise acquired Certara shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Certara, Inc. (“Certara” or the “Company”) (NASDAQ:CERT) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
[LEARN MORE ABOUT THE INVESTIGATION]
What Happened?
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara stated that it saw “softer performance from Tier 1 customers in MIDD services” and that services performance was “mixed.” The Company also announced their exit from the regulatory business in their service segment. In response to a question about consistency between software and services performance, the Company stated that there had been “a lot of inconsistency and back and forth” over the last few quarters. On this news, the price of Certara shares declined by $1.18 per share, or approximately 19%, from $6.31 per share on May 8, 2026 to close at $5.13 on May 11, 2026.
What Should I Do?
At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.
If you purchased or otherwise acquired Certara securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[LEARN MORE ABOUT SECURITES CLASS ACTIONS]
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Certara, Inc. (“Certara” or the “Company”) (NASDAQ:CERT) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services re.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Certara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara said that it saw "softer performance from Tier 1 customers in MIDD services" and that services performance was "mixed." The Company also announced its exit from the regulatory business in their service segment. In response to a question about consistency between software and services performance, Certara said that there had been "a lot of inconsistency and back and forth" over the last few quarters.
On this news, Certara's stock price fell $1.18 per share, or approximately 19%, to close at $5.13 on May 11, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Certara, Inc. (“Certara” or the “Company”) (NASDAQ:CERT) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
[LEARN MORE ABOUT THE INVESTIGATION]
What Happened?
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara stated that it saw “softer performance from Tier 1 customers in MIDD services” and that services performance was “mixed.” The Company also announced their exit from the regulatory business in their service segment. In response to a question about consistency between software and services performance, the Company stated that there had been “a lot of inconsistency and back and forth” over the last few quarters. On this news, the price of Certara shares declined by $1.18 per share, or approximately 19%, from $6.31 per share on May 8, 2026 to close at $5.13 on May 11, 2026.
What Should I Do?
At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.
If you purchased or otherwise acquired Certara securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[LEARN MORE ABOUT SECURITES CLASS ACTIONS]
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
LOS ANGELES, May 24, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Certara, Inc. (“Certara” or “the Company”) (NASDAQ: CERT) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Certara reported its Q1 2026 financial results on May 11, 2026. The Company revealed a decline in services revenues and bookings. The Company blamed "softer performance from Tier 1 customers in MIDD services" Based on this news, shares of Certara fell by 19% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335 [email protected]
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Certara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara said that it saw “softer performance from Tier 1 customers in MIDD services” and that services performance was “mixed.” The Company also announced its exit from the regulatory business in their service segment. In response to a question about consistency between software and services performance, Certara said that there had been “a lot of inconsistency and back and forth” over the last few quarters.
On this news, Certara’s stock price fell $1.18 per share, or approximately 19%, to close at $5.13 on May 11, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Certara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara said that it saw "softer performance from Tier 1 customers in MIDD services" and that services performance was "mixed." The Company also announced its exit from the regulatory business in their service segment. In response to a question about consistency between software and services performance, Certara said that there had been "a lot of inconsistency and back and forth" over the last few quarters.
On this news, Certara's stock price fell $1.18 per share, or approximately 19%, to close at $5.13 on May 11, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Ahead of hurricane season, Duke Energy Foundation awards $500,000 to strengthen storm preparedness across North Carolina Ahead of hurricane season, Duke Energy Foundation awards $500,000 to strengthen storm preparedness across North Carolina PR Newswire
CHARLOTTE, N.C., May 28, 2026
Since 2016, the Duke Energy Foundation has given more than $8.9 million to support emergency preparedness and storm response in North Carolina, /PRNewswire/ -- With the 2026 hurricane season beginning June 1, the Duke Energy Foundation is awarding $500,000 in grants to 20 nonprofit and local government partners across North Carolina to strengthen emergency preparedness, improve coordination during severe weather and support faster, safer recovery for communities statewide.
Our view
Kendal Bowman, Duke Energy's North Carolina president: "Preparation saves lives and shortens recovery. By investing in trusted local partners across North Carolina, we're helping communities strengthen emergency readiness before storms hit and ensuring responders have the tools they need when every minute counts."Positive response
Allison Taylor, regional executive, American Red Cross North Carolina Region: "The American Red Cross is grateful to Duke Energy for investing in the readiness of our region. Their support helps families and communities better prepare for storms and other disasters across the Carolinas."Lacy Pate, director of Disaster Recovery and Grant Assistance, NCACC Member Services Foundation: "We're grateful to the Duke Energy Foundation for its investment in the 100 Counties Prepared program. Because disaster recovery begins and ends at the local level, this support strengthens the readiness of county leaders – equipping them with the tools, relationships and knowledge to improve coordination, build resilience and respond when it matters most. With stronger local capacity, counties will be better positioned to act quickly, coordinate effectively and support their communities through every phase of storm response and recovery."Chief Andy Lipscomb, Davie Rescue Squad: "We are incredibly grateful to the Duke Energy Foundation for their generous $25,000 investment in Davie County's storm preparedness and rapid response capabilities. These funds will directly support the Davie Rescue Swiftwater Team by enhancing equipment and operational readiness for severe weather and flooding events. Partnerships like this strengthen our ability to protect lives, respond quickly during emergencies and better serve the citizens of Davie County when they need us most." High-impact investments: Funding will be used to:
American Red Cross: Support disaster preparedness, response and recovery programs across North Carolina, including volunteer training, emergency sheltering, supplies and community educationBurke County: Repair a rescue boat and purchase a drone to improve water-based response, wildfire monitoring and overall emergency response capabilitiesCaswell County: Build and equip a mobile shelter support unit with essential supplies and equipment to improve shelter readiness and operations during emergenciesCity of Winston-Salem: Build a mobile shelter support unit with a trailer and supplies to enable faster deployment and operation of emergency shelters during storms and power outagesCleveland County: Install a new outdoor warning siren in an unserved area and relocate an existing siren to improve emergency alerts and public safety during severe weatherCraven County Emergency Services: Purchase a drone to support search and rescue operations and conduct rapid damage assessments following stormsDavie Rescue Squad: Purchase upgraded swift water rescue equipment and protective gear, along with supporting advanced training for respondersEastern Band of Cherokee Indians: Deliver a multiday, contractor-led training program to strengthen incident planning, coordination and response capabilities among regional emergency responders during stormFriends and Neighbors of Swannanoa: Develop and pilot a scalable Community Emergency Response Team (CERT) starter kit, including training materials, equipment and instructor development, while launching and equipping a new CERT team in SwannanoaHenderson-Vance Emergency Operations: Purchase chainsaws and PPE for debris removal, expand shelter supplies and provide disaster preparedness kits and training to residentsHoke County: Replace outdated interoperable radios to ensure reliable emergency communications during storms and power outagesHuntsville Volunteer Fire Department: Purchase a UTV and fire rescue skid unit to improve access and response capabilities for wildland fires and remote rescuesInformation Technology Disaster Resource Center: Install permanent communications infrastructure at priority resiliency hubs, expand connectivity for vulnerable populations and document a scalable model for disaster-prone communitiesJohnston County Emergency Services: Purchase and distribute 250 storm preparedness kits with essential supplies to help vulnerable residents better prepare for severe weather and power outagesLawsonville Volunteer Fire Department: Purchase a fully equipped traffic control trailer to quickly secure hazardous areas, manage roadway safety and respond more efficiently during storm-related emergenciesMcDowell County: Equip emergency response vehicles with wildfire suppression tools, protective gear and specialty equipment to improve wildfire mitigation, response and community resilienceMoore County: Create a mobile disaster shelter support trailer stocked with supplies to expand shelter capacity and improve deployment during emergenciesNorth Carolina Association of County Commissioners Member Services Foundation: Expand a statewide storm preparedness initiative by supporting regional trainings, developing planning materials, and providing hands-on technical assistance to county leaders.Orange County: Install additional flood monitoring sensors to improve real-time data collection and early warning alerts in high-risk flood areasWilmington Area Rebuilding Ministry: Complete targeted home repairs that address storm-related structural risks for low-income homeowners, improving safety and reducing future damage and emergency incidentsDuke Energy Foundation
Duke Energy Foundation provides nearly $30 million annually in philanthropic support to meet the needs of communities where Duke Energy customers live and work. The Foundation is funded by Duke Energy shareholders.
Duke Energy
Duke Energy (NYSE: DUK), a Fortune 150 company headquartered in Charlotte, N.C., is one of America's largest energy holding companies. The company's electric utilities serve 8.7 million customers in North Carolina, South Carolina, Florida, Indiana, Ohio and Kentucky, and collectively own 55,700 megawatts of energy capacity. Its natural gas utilities serve 1.6 million customers in North Carolina, South Carolina, Ohio and Kentucky.
Duke Energy is executing an energy modernization strategy, keeping customer value at the forefront as it invests in electric grid upgrades and efficient generation resources to strengthen the system and serve growing energy needs.
More information is available at duke-energy.com. Follow Duke Energy on X, LinkedIn, Instagram, TikTok and Facebook for stories about the people and innovations powering its communities.
Contact: Madison McDonald
24-Hour: 800.559.3853
View original content to download multimedia:https://www.prnewswire.com/news-releases/ahead-of-hurricane-season-duke-energy-foundation-awards-500-000-to-strengthen-storm-preparedness-across-north-carolina-302784627.html
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Certara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara said that it saw “softer performance from Tier 1 customers in MIDD services” and that services performance was “mixed.” The Company also announced its exit from the regulatory business in their service segment. In response to a question about consistency between software and services performance, Certara said that there had been “a lot of inconsistency and back and forth” over the last few quarters.
On this news, Certara’s stock price fell $1.18 per share, or approximately 19%, to close at $5.13 on May 11, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Certara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara said that it saw "softer performance from Tier 1 customers in MIDD services" and that services performance was "mixed." The Company also announced its exit from the regulatory business in their service segment. In response to a question about consistency between software and services performance, Certara said that there had been "a lot of inconsistency and back and forth" over the last few quarters.
On this news, Certara's stock price fell $1.18 per share, or approximately 19%, to close at $5.13 on May 11, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
3 Momentum Stocks That Could Soar Post-Market VolatilityCertara NASDAQ: CERT executives outlined the company’s strategic realignment, artificial intelligence initiatives and cost priorities during a discussion at Jefferies’ 2026 Global Healthcare Conference, with newly appointed Chief Executive Officer Jon Resnick saying the company is focused on creating clearer growth engines and improving execution.
Resnick, who said he started as CEO on Jan. 1, described the first several months as “pretty active” and said Certara has been speaking with customers, regulators and internal teams about growth opportunities. He said the company’s mission is to “disrupt clinical trials” or “transform clinical trials, clinical development for good.”
Get Certara alerts:
Certara Reorganizes Around ACE and MID3 Simulations Plus Stock Drops 15% Despite EPS BeatResnick said Certara has realigned around two strategic growth engines: ACE, or accelerating clinical evidence, and MID3, or model-informed drug development and discovery.
ACE is focused on helping clients manage data “from protocol to submission,” improve efficiency and unlock data more quickly, Resnick said. He cited Certara assets including Phoenix, Pinnacle, CoAuthor and GlobalSubmit as part of that effort.
Are These 3 Small Momentum Stocks Setting Up Big Gains?MID3, which Resnick said is the area Certara is “probably best known for,” is focused on using computational biology and biosimulation to change how clinical development is conducted. He said the company sees growth opportunities in discovery, where it has made significant investment.
Asked about Phoenix, Resnick said the product has “two distinct applications.” One component is a computational engine tied to PK/PD and population pharmacokinetic analysis, while another broader application suite is focused on data management and computational mechanics. He said most Phoenix customers will work through the data management side, while PopPK scientists will be linked more directly with one application.
Resnick said the realignment is intended to create “clarity, strategic growth, and accountability” and should simplify operations over time. He said the company is also adjusting its go-to-market teams to allow more specialty-led engagement and more direct involvement from subject matter experts and scientists.
Chief Financial Officer John Gallagher said the realignment gives Certara an opportunity to unify some previously disparate operations, which he linked to operating metrics the company is using to support growth in the second half of the year.
Sales Strategy Centers on Scientist-to-Scientist Engagement Resnick said Certara sees a large opportunity in the clinical trial market, which he described as a $230 billion addressable market. He said regulators are increasingly open to newer approaches beyond traditional clinical development methods.
He said biosimulation is already common in areas such as drug-drug interaction and dosing optimization, and Certara sees opportunities to expand into areas including pediatrics, pregnancy and lactation, and organ impairment.
Resnick said Certara often loses business not to competitors or on price, but because clients choose traditional approaches. As a result, he said the company’s “highest single indicator of success” is getting its scientists directly in front of decision-makers at client companies.
He said Certara has brought PopPK, QSP and PBPK teams together, along with related technologies, to better respond to client challenges. The company has also changed incentives to reduce barriers between technology and services teams and encourage what Resnick called a “flywheel effect.”
AI Efforts Span Products and Internal Operations Resnick said Certara believes frontier AI models will be strong in reasoning and logic, but that significant work remains in the vertical “last mile of execution.” He said Certara’s data, domain expertise, embedded workflows, publications and relationships with scientists and regulators provide a position to reinforce that vertical stack.
He said Certara is embedding AI into existing products, creating new modules and exploring native AI products. Resnick cited Certara IQ in QSP, CODEx as a data component, D360 re-platforming, cloud-based initiatives and AI-centric reporting capabilities in the cloud version of Phoenix.
Resnick also discussed the company’s acquisition of Vyasa, saying it has helped create an “AI-first mindset” inside Certara. He said Dr. Krishnan Raman was named chief AI officer on the company’s most recent earnings call and is leading work on a unifying data-layer asset that would allow Certara’s software and technology products to communicate more holistically.
Gallagher said Certara is also looking to use AI internally across R&D, finance, HR and IT to find productivity gains that could partially offset investment in R&D.
Demand, Bookings and Cost Priorities Gallagher said the overall end markets are “in good shape,” pointing to a positive biotech funding environment aside from a recent “blip” and a big pharma spending environment that Certara views as healthy.
He acknowledged volatility in Certara’s results, with software down in the fourth quarter and up in the first quarter, while services moved in the opposite direction. Gallagher said trailing 12-month bookings provide a better view of stabilization and potential acceleration.
Gallagher said first-quarter software revenue grew 7%, above the company’s expectations, and that Certara now views its software plan for the year as “a bit better” than previously expected. For services, he said trailing 12-month bookings indicate low-single-digit growth, and that first-half choppiness is playing out in line with expectations.
Resnick said Certara is focused internally on annual recurring revenue for software and new software sales. On services, he said the focus is on opportunity generation and pipeline generation, including getting scientific teams back into the market to engage directly with customers.
Gallagher said Certara continues to pursue about $10 million of cost reductions while maintaining R&D investment. He said efficiencies may come from cost of sales, G&A, sales and marketing, and back-office unification. He said R&D at about 10% to 11% of sales is a reasonable placeholder for this year.
Portfolio Positioning and M&A Resnick said Certara is no longer accurately characterized as primarily a small-molecule company. He estimated that roughly 60% of the business is small molecule and 40% is large molecule. He said some products, including Phoenix and Pinnacle, are largely agnostic to molecule type, while Simcyp is approximately 30% large molecule today.
He also said QSP is “almost exclusively” a biologics area, and products such as D360 and Chemaxon have added more large-molecule-focused innovation.
Asked about acquisitions, Resnick said M&A is “not the near-term priority.” He said Certara’s focus is on improving returns from organic investment and getting its existing teams operating effectively. He said the company would not rule out acquisitions that accelerate a near-adjacent market, but said the priority is organic execution.
About Certara NASDAQ: CERTCertara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company's platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.
The company's offerings are divided into software tools and consulting services.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Certara Right Now?Before you consider Certara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list.
While Certara currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Certara, Inc. ("Certara" or "the Company") (NASDAQ: CERT) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Certara reported its Q1 2026 financial results on May 11, 2026. The Company revealed a decline in services revenues and bookings. The Company blamed "softer performance from Tier 1 customers in MIDD services" Based on this news, shares of Certara fell by 19% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Certara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara said that it saw “softer performance from Tier 1 customers in MIDD services” and that services performance was “mixed.” The Company also announced its exit from the regulatory business in their service segment. In response to a question about consistency between software and services performance, Certara said that there had been “a lot of inconsistency and back and forth” over the last few quarters.
On this news, Certara’s stock price fell $1.18 per share, or approximately 19%, to close at $5.13 on May 11, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Certara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services revenue declined 4% year-over-year to $57.2 million, while services bookings declined 14% year-over-year to $66.6 million. In discussing the quarter, Certara said that it saw "softer performance from Tier 1 customers in MIDD services" and that services performance was "mixed." The Company also announced its exit from the regulatory business in their service segment. In response to a question about consistency between software and services performance, Certara said that there had been "a lot of inconsistency and back and forth" over the last few quarters.
On this news, Certara's stock price fell $1.18 per share, or approximately 19%, to close at $5.13 on May 11, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Certara, Inc. ("Certara" or "the Company") (NASDAQ: CERT) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Certara reported its Q1 2026 financial results on May 11, 2026. The Company revealed a decline in services revenues and bookings. The Company blamed "softer performance from Tier 1 customers in MIDD services" Based on this news, shares of Certara fell by 19% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com
